BAX — Baxter International Inc.
Healthcare · ETF XLV · as of 2026-09-22
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; administrative sets; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed sy...
Price & today
| Stock today | +3.27% |
| Sector ETF today | +0.52% |
| Residual (stock-specific) | +2.75% |
Sector correlation
| 20-day correlation with XLV | 0.40 |
| 60-day correlation with XLV | 0.40 |
| Status | normal |
Decoupling fires when 60d corr − 20d corr > 0.20: stock used to track its sector but the relationship has weakened recently.
Technicals
| 10 EMA | $23.72 |
| 20 EMA | $24.35 |
| 50 EMA | $24.30 |
| EMA stack | NEUTRAL |
| RSI(14) | 40.9 |
| 52-week high distance | -27.54% |
| 52-week low distance | +50.54% |
Signals
| Market F&G | 45.1 |
| Bull% | 12.9% |
| OVTLYR status | SELL (24d) |
| Sector rank | #282 |
| Next earnings | 2026-10-28 (TNS, 35d) |
MarketSmith metrics - our compute
What do these abbreviations mean?
- RS Rating
- - IBD-style relative strength vs SPY (weighted 3/6/9/12-mo). 70+ = leaders pool, 80+ = strong.
- ADR%
- - average daily range over 20 days. 4%+ = the fast movers the playbook prefers (selection order, not a gate).
- RMV (tight)
- - Relative Measured Volatility, 15 bars, scaled 0-100. <15 = tight coiled base (green), <35 moderate, high = loose/expanding - not a base right now.
- Ext (ATR>20EMA)
- - how many ATRs price sits above its 20-EMA. ≤1 = in value (green), >2 = extended/chasing (red) - prefer a pullback.
- Rel Vol
- - latest volume vs the 50-day average. 100% = normal; 140%+ = breakout confirmation.
- U/D 50d / 25d
- - up-day vs down-day volume over the window. 1.1+ = net accumulation (institutions buying); under 0.9 on the 25d = net selling.
- Accum/Dist 25d
- - heavy-volume up days vs heavy-volume down days in the last 25 sessions (close moved 0.2%+ on above-average volume). The institutional-participation footprint; 5+ distribution days = O'Neil caution line.
- LoD dist
- - close distance above the day low in % of ATR (100 = one full ATR off the low). High = strong close.
- Off/Above 52w
- - trend-template legs: within 25% of the 52-week high, at least 25% above the 52-week low.
- Trend 8/8
- - all 8 Minervini Trend Template criteria pass. Discovery floor, NOT an entry signal - entries come from the VCP pivot.
- Base len (VCP)
- - weeks since the VCP base started on the latest scan. 10wk+ bases carry the edge; short stacked bases test below random.
Fundamentals & valuation - reference, not entry inputs
Company data - context read, not entry inputs
Quarterly EPS - earnings acceleration
A dash in %Chg is deliberate: the year-ago figure was a loss, so a growth % would be meaningless. A dash in Sales means we have no revenue figure for that quarter - read it as a gap in our data, not as zero revenue.
| Quarter | EPS ($) | %Chg YoY | Sales ($M) | %Chg |
|---|---|---|---|---|
| Nov-24 | 0.80 | +18% | 2,699.0 | +4% |
| Feb-25 | 0.58 | -34% | 2,753.0 | +1% |
| May-25 | 0.55 | -15% | 2,625.0 | +5% |
| Jul-25 | 0.59 | -13% | 2,810.0 | +4% |
| Oct-25 | 0.69 | -14% | 2,835.0 | +5% |
| Feb-26 | 0.44 | -24% | 2,974.0 | +8% |
| Apr-26 | 0.36 | -35% | 2,701.0 | +3% |
| Jul-26 | 0.56 | -5% | 2,960.0 | +5% |
eps_actual (the figure MarketSmith/Deepvue show) - whether a given quarter is GAAP or excludes a one-off follows the filing, so it can sit either side of another vendor's number; AAPL's Oct-24 row, the Sep-2024 fiscal quarter, is $0.97 here - GAAP, including the EU tax charge - where TradingView's year implies $1.64 · Sales ($M) = SEC EDGAR quarterly revenue (fiscal Q4 derived as FY minus 9-mo) · quarter = report month · %Chg blank = prior-year base under $0.05 (not meaningful).Recent news - our DB (Finnhub + OVTLYR)
- Sep 09 + Intravenous Immunoglobulin Market Size Worth USD 30.83 Billion by 2035, Growing at 7.49% CAGR – SNS Insider GlobeNewswire Inc.
- Sep 07 + BAX Raises 2026 Outlook as Strong Q2 Growth Offsets Margin Pressure Zacks Investment Research
- Sep 07 · BAX Raises 2026 Outlook as Strong Q2 Growth Offsets Margin Pressure Yahoo
- Sep 07 + Drug Reconstitution Systems Market Trends, Shares and Growth Opportunities Worldwide 2026-2035 Featuring Profiles of Baxter, ICU Medical, B. Braun, Vetter Pharma, Nipro, SCHOTT-KAISHA GlobeNewswire Inc.
- Sep 07 · Drug Reconstitution Systems Market Trends, Shares and Growth Opportunities Worldwide 2026-2035 Featuring Profiles of Baxter, ICU Medical, B. Braun, Vetter Pharma, Nipro, SCHOTT-KAISHA Yahoo
- Sep 02 · 3 Value Stocks We Keep Off Our Radar Yahoo
- Sep 01 · 3 Healthcare Stocks We Keep Off Our Radar Yahoo
- Aug 30 · Everything I Learned from My Hot Chart Summer, and How My 21 Stocks Picks Have Performed. Yahoo